GoAI
Get started
Immuron Limited logo

Immuron Limited

IMRN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.12

−$0.06 · -5.08%

Aug 21, 4:00 PM ET

IMRN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

47

Neutral

Sentiment

53

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
AU

Market position

Day range

Current $1.12

52-week range

Current $1.12

Open
$1.17
Previous close
$1.18
Volume
7.26K
Market cap
7.22M USD
50-day average
$1.1346
-1.29% below average
200-day average
$1.045
+7.17% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-1.82×
P/B (TTM)
0.71×
P/S (TTM)
1.17×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
63.69%
Operating margin
-68.38%
Net margin
-62.14%

Financial health

Debt / equity
0×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends681%-1658%-3997%-6336%Gross margin, FY2021: -456.22%Gross margin, FY2022: 68.41%Gross margin, FY2023: 96.42%Gross margin, FY2024: 68.06%Gross margin, FY2025: 65.39%Operating margin, FY2021: -5748.48%Operating margin, FY2022: -375.05%Operating margin, FY2023: -197.75%Operating margin, FY2024: -118.32%Operating margin, FY2025: -73.34%Net margin, FY2021: -5751.61%Net margin, FY2022: -373.01%Net margin, FY2023: -209.81%Net margin, FY2024: -141.49%Net margin, FY2025: -71.58%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -456.22%. Gross margin FY2022 68.41%. Gross margin FY2023 96.42%. Gross margin FY2024 68.06%. Gross margin FY2025 65.39%. Operating margin FY2021 -5748.48%. Operating margin FY2022 -375.05%. Operating margin FY2023 -197.75%. Operating margin FY2024 -118.32%. Operating margin FY2025 -73.34%. Net margin FY2021 -5751.61%. Net margin FY2022 -373.01%. Net margin FY2023 -209.81%. Net margin FY2024 -141.49%. Net margin FY2025 -71.58%.

Income trends

Revenue

7.29M USD+48.63%

Operating income

−5.34M USD+7.87%

Net income

−5.22M USD+24.81%
Income trends across reported periods8.85M USD2.59M USD−3.68M USD−9.95M USDRevenue, FY2021: 145.78K USDRevenue, FY2022: 765.19K USDRevenue, FY2023: 1.8M USDRevenue, FY2024: 4.9M USDRevenue, FY2025: 7.29M USDOperating income, FY2021: −8.38M USDOperating income, FY2022: −2.87M USDOperating income, FY2023: −3.57M USDOperating income, FY2024: −5.8M USDOperating income, FY2025: −5.34M USDNet income, FY2021: −8.38M USDNet income, FY2022: −2.85M USDNet income, FY2023: −3.79M USDNet income, FY2024: −6.94M USDNet income, FY2025: −5.22M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 145.78K USD. Revenue FY2022 765.19K USD. Revenue FY2023 1.8M USD. Revenue FY2024 4.9M USD. Revenue FY2025 7.29M USD. Operating income FY2021 −8.38M USD. Operating income FY2022 −2.87M USD. Operating income FY2023 −3.57M USD. Operating income FY2024 −5.8M USD. Operating income FY2025 −5.34M USD. Net income FY2021 −8.38M USD. Net income FY2022 −2.85M USD. Net income FY2023 −3.79M USD. Net income FY2024 −6.94M USD. Net income FY2025 −5.22M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue7.29M USD4.9M USD1.8M USD765.19K USD145.78K USD
Cost of goods sold2.52M USD1.57M USD64.63K USD241.69K USD810.84K USD
Gross profit4.77M USD3.34M USD1.74M USD523.5K USD−665.06K USD
Research and development3.6M USD5.38M USD2.59M USD657.72K USD1.37M USD
Selling, general, and administrative7.94M USD6.59M USD5.15M USD3.94M USD6.38M USD
Operating expenses10.11M USD9.14M USD5.31M USD3.39M USD7.71M USD
Interest income135.87K USD327.76K USD116.32K USD21.79K USD9.2K USD
Interest expense7.31K USD7.58K USD9.65K USD6.18K USD13.76K USD
Depreciation and amortization49.69K USD45.98K USD48.66K USD26.61K USD5.04K USD
Operating income−5.34M USD−5.8M USD−3.57M USD−2.87M USD−8.38M USD
Net income−5.22M USD−6.94M USD−3.79M USD−2.85M USD−8.38M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
33%
1 beat, 2 misses, 0 met estimates
Average EPS surprise
-1492.16%
3 comparable reports
Latest EPS result
-0.2
Estimate -0.01 · Miss by 2586.23%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0-0.11-0.21-0.31Q1 '23No estimateQ3 '23No estimateQ1 '24No estimateQ3 '24No estimateQ1 '25MissQ3 '25BeatQ1 '26MissQ3 '26Estimate
Q1 2023, reported Feb 28, 2023: actual -0.118, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual -0.106, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Feb 28, 2024: actual -0.245, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual -0.013, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 28, 2025: actual -0.272, estimate -0.013, surprise -1941.49%, Miss. Q3 2025, reported Aug 28, 2025: actual -0.007, estimate -0.013, surprise +51.24%, Beat. Q1 2026, reported Feb 25, 2026: actual -0.199, estimate -0.007, surprise -2586.23%, Miss. Q3 2026, reported Aug 28, 2026: actual —, estimate -0.004, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.2M2.19M1.18M169.52KQ1 '23No estimateQ3 '23No estimateQ1 '24No estimateQ3 '24MissQ1 '25BeatQ3 '25BeatQ1 '26BeatQ3 '26Estimate
Q1 2023, reported Feb 28, 2023: actual 199.43K USD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 405.45K USD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Feb 28, 2024: actual 1.6M USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual 1.7M USD, estimate 2.41M USD, surprise -29.64%, Miss. Q1 2025, reported Feb 28, 2025: actual 2.49M USD, estimate 1.67M USD, surprise +49.57%, Beat. Q3 2025, reported Aug 28, 2025: actual 2.14M USD, estimate 2M USD, surprise +6.98%, Beat. Q1 2026, reported Feb 25, 2026: actual 2.97M USD, estimate 2.89M USD, surprise +3.06%, Beat. Q3 2026, reported Aug 28, 2026: actual —, estimate 2.75M USD, surprise —, Comparison unavailable.

IMRN news

defenseworld.net

Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) Financial Analysis

Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Immuron (NASDAQ: IMRN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on…

Read source
globenewswire.com

Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The Emerging Growth…

Read source
globenewswire.com

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth…

Read source
globenewswire.com

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food and…

Read source

IMRN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research IMRN

research.disclaimer